{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Genetic&page=5",
    "query": {
      "condition": "Skin Diseases, Genetic",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1834,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Genetic&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Diseases%2C+Genetic&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T21:02:36.975Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07266805",
      "title": "Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)"
      ],
      "interventions": [
        {
          "name": "Deucrictibant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharvaris Netherlands B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-10-16",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07266805"
    },
    {
      "nct_id": "NCT07700966",
      "title": "A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Prademagene Zamikeracel",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Abeona Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 250,
      "start_date": "2025-07-25",
      "completion_date": "2045-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07700966"
    },
    {
      "nct_id": "NCT00457015",
      "title": "Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Phosphate Buffer Saline (PBS), pH 7.0",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2007-04-01",
      "completion_date": "2008-06-01",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 42,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Crescent City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457015"
    },
    {
      "nct_id": "NCT07398508",
      "title": "NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Menkes Disease"
      ],
      "interventions": [
        {
          "name": "Droxidopa Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Stephen G. Kaler",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 6,
      "start_date": "2026-08-10",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07398508"
    },
    {
      "nct_id": "NCT07366086",
      "title": "Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteogenesis Imperfecta"
      ],
      "interventions": [
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Calcium",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "5 Years to 19 Years"
      },
      "enrollment_count": 71,
      "start_date": "2026-03-18",
      "completion_date": "2028-04-19",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07366086"
    },
    {
      "nct_id": "NCT07262983",
      "title": "Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyper IgE Syndrome From STAT3 Mutation",
        "Job s Syndrome",
        "HIES",
        "Lupus",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "baricitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-10-21",
      "completion_date": "2030-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07262983"
    },
    {
      "nct_id": "NCT02178969",
      "title": "Short Term Observational Study in DEB Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 29,
      "start_date": "2014-06-24",
      "completion_date": "2015-02-23",
      "has_results": false,
      "last_update_posted_date": "2021-03-17",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178969"
    },
    {
      "nct_id": "NCT03056755",
      "title": "Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 383,
      "start_date": "2017-08-29",
      "completion_date": "2024-11-12",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 25,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03056755"
    },
    {
      "nct_id": "NCT05180708",
      "title": "A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pachyonychia Congenita"
      ],
      "interventions": [
        {
          "name": "QTORIN 3.9% rapamycin anhydrous gel",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palvella Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2021-11-29",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        },
        {
          "city": "Fridley",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05180708"
    },
    {
      "nct_id": "NCT03742414",
      "title": "Seal, Stopping Eczema and Allergy Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eczema, Infantile",
        "Eczema",
        "Atopic Dermatitis Eczema",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Tri-lipid skin barrier cream (Epiceram)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluticasone propionate Cream 0.05%",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Standard of Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "Kari Nadeau, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Week",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "1 Week to 12 Weeks"
      },
      "enrollment_count": 398,
      "start_date": "2021-06-30",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-17T21:02:36.975Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742414"
    }
  ]
}